Published in Prostate on May 29, 2012
Identification of intracellular proteins and signaling pathways in human endothelial cells regulated by angiotensin-(1-7). J Proteomics (2015) 1.09
The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. Clin Sci (Lond) (2014) 1.03
Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J Control Release (2013) 0.85
Angiotensin-(1-7) prevents radiation-induced inflammation in rat primary astrocytes through regulation of MAP kinase signaling. Free Radic Biol Med (2013) 0.83
Lysyl oxidase propeptide stimulates osteoblast and osteoclast differentiation and enhances PC3 and DU145 prostate cancer cell effects on bone in vivo. J Cell Commun Signal (2015) 0.82
Bone marrow as a metastatic niche for disseminated tumor cells from solid tumors. Bonekey Rep (2015) 0.81
G-protein coupled receptors of the renin-angiotensin system: new targets against breast cancer? Front Pharmacol (2015) 0.78
Angiotensin and systems thinking: wrapping your mind around the big picture. Ochsner J (2013) 0.76
AAV-Mediated angiotensin 1-7 overexpression inhibits tumor growth of lung cancer In Vitro and In Vivo. Oncotarget (2016) 0.75
Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain. Pain (2016) 0.75
The ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Pleiotropic Roles in Cancer. Front Physiol (2017) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Increased expression of TGF-beta 2 in osteoblasts results in an osteoporosis-like phenotype. J Cell Biol (1996) 2.36
Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol (2011) 2.21
Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med (1999) 2.13
A renaissance in the medical treatment of advanced prostate cancer. Oncology (Williston Park) (2010) 2.05
Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J Cell Biochem (2005) 1.72
Examining the metastatic niche: targeting the microenvironment. Semin Oncol (2010) 1.71
Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res (2008) 1.67
Advances in the biology of bone metastasis: how the skeleton affects tumor behavior. Bone (2010) 1.54
Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther (2009) 1.52
Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis (2004) 1.37
Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer (2010) 1.33
The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol (2009) 1.31
Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res (2007) 1.28
The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem (2007) 1.26
The anti-tumour activity of bisphosphonates. Cancer Treat Rev (2002) 1.25
VEGF receptor 1 signaling is essential for osteoclast development and bone marrow formation in colony-stimulating factor 1-deficient mice. Proc Natl Acad Sci U S A (2005) 1.23
Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension (1998) 1.21
Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res (2004) 1.19
Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res (2005) 1.17
VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and beta3-integrin. Matrix Biol (2008) 1.11
Angiotensin-(1-7) reduces fibrosis in orthotopic breast tumors. Cancer Res (2010) 1.08
Vascular endothelial growth factor regulates osteoblast survival - evidence for an autocrine feedback mechanism. J Orthop Surg Res (2009) 1.07
Phase I and pharmacokinetic study of angiotensin-(1-7), an endogenous antiangiogenic hormone. Clin Cancer Res (2009) 1.04
Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab (2008) 1.04
Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension (2003) 1.01
Opposing actions of angiotensins on angiogenesis. Life Sci (2000) 1.00
Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res (2011) 0.98
Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res (2010) 0.97
Vascular endothelial growth factor content in metastasizing and nonmetastasizing Dunning prostatic adenocarcinoma. Prostate (2000) 0.87
Novel targeted therapies for prostate cancer. Urol Clin North Am (2010) 0.86
Role of the VEGF-Flt-1-FAK pathway in the pathogenesis of osteoclastic bone destruction of giant cell tumors of bone. J Orthop Surg Res (2010) 0.83
The application of nanotechnology for the treatment of metastatic prostate cancer. BJU Int (2009) 0.82
New developments for treatment and prevention of bone metastases. Curr Opin Oncol (2011) 0.82
Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies. Prostate (2010) 0.81
Bone metastases in prostate cancer: a targeted approach. Curr Opin Oncol (2007) 0.81
Research in castration-resistant prostate cancer: what does the future hold? Curr Oncol (2010) 0.79
Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res (2007) 3.30
Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest (2005) 3.25
Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell (2004) 3.21
In vivo regeneration of murine prostate from dissociated cell populations of postnatal epithelia and urogenital sinus mesenchyme. Proc Natl Acad Sci U S A (2003) 3.19
Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest (2007) 3.01
Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem (2008) 2.87
Iron and cancer: more ore to be mined. Nat Rev Cancer (2013) 2.40
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
Effects of anesthetics on systemic hemodynamics in mice. Am J Physiol Heart Circ Physiol (2004) 2.32
Apoptosis regulators Bim and Fas function concurrently to control autoimmunity and CD8+ T cell contraction. Immunity (2008) 2.26
Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid (2002) 2.18
Mesothelin expression in human lung cancer. Clin Cancer Res (2007) 2.10
Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss. J Biol Chem (2008) 2.09
Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A (2010) 1.99
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood (2008) 1.97
Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension (2004) 1.96
Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med (2010) 1.94
Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation (2005) 1.92
Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol (2005) 1.92
Improved detection of apoptotic cells in archival paraffin sections: immunohistochemistry using antibodies to cleaved caspase 3. J Histochem Cytochem (2002) 1.92
An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res (2011) 1.91
ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. Am J Physiol Regul Integr Comp Physiol (2007) 1.85
Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol (2005) 1.84
Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging (2013) 1.82
Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol (2005) 1.81
Serum ferritin: Past, present and future. Biochim Biophys Acta (2010) 1.80
Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A (2006) 1.77
ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation (2004) 1.76
Cholesterol-regulated translocation of NPC1L1 to the cell surface facilitates free cholesterol uptake. J Biol Chem (2005) 1.75
Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int (2005) 1.71
Diphtheria toxin-murine granulocyte-macrophage colony-stimulating factor-induced hepatotoxicity is mediated by Kupffer cells. Mol Cancer Ther (2004) 1.68
An unliganded thyroid hormone beta receptor activates the cyclin D1/cyclin-dependent kinase/retinoblastoma/E2F pathway and induces pituitary tumorigenesis. Mol Cell Biol (2005) 1.67
Iron chelators in cancer chemotherapy. Curr Top Med Chem (2004) 1.61
Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Mol Cancer Ther (2009) 1.52
TIM-2 is expressed on B cells and in liver and kidney and is a receptor for H-ferritin endocytosis. J Exp Med (2005) 1.52
The effect of botulinum neurotoxin-A on blood flow in rats: a potential mechanism for treatment of Raynaud phenomenon. J Hand Surg Am (2012) 1.50
Prostate cancer risk associated loci in African Americans. Cancer Epidemiol Biomarkers Prev (2009) 1.49
Evaluation of in vivo rotator cuff muscle function after acute and chronic detachment of the supraspinatus tendon: an experimental study in an animal model. J Bone Joint Surg Am (2011) 1.47
Ferritin for the clinician. Blood Rev (2008) 1.46
Demand for continuing medical education programs on cancer care among primary care physicians in North Carolina. N C Med J (2004) 1.46
Impaired heart rate baroreflex in older rats: role of endogenous angiotensin-(1-7) at the nucleus tractus solitarii. Hypertension (2005) 1.45
Complex regional pain syndrome of the upper extremity. J Hand Surg Am (2011) 1.42
Chronic treatment with the G protein-coupled receptor 30 agonist G-1 decreases blood pressure in ovariectomized mRen2.Lewis rats. Endocrinology (2009) 1.42
Long-term survival following a single treatment of kidney tumors with multiwalled carbon nanotubes and near-infrared radiation. Proc Natl Acad Sci U S A (2009) 1.41
Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol (2005) 1.40
Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci U S A (2002) 1.40
Gene expression of myogenic regulatory factors following intramuscular injection of botulinum A toxin in juvenile rats. Neurosci Lett (2005) 1.39
Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest (2006) 1.37
Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis (2004) 1.37
Pancreatic cancer cells express 25-hydroxyvitamin D-1 alpha-hydroxylase and their proliferation is inhibited by the prohormone 25-hydroxyvitamin D3. Carcinogenesis (2004) 1.37
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage. Microb Pathog (2007) 1.36
Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis (2007) 1.35
Regulatory effects of ferritin on angiogenesis. Proc Natl Acad Sci U S A (2009) 1.34
Topology of NGEP, a prostate-specific cell:cell junction protein widely expressed in many cancers of different grade level. Cancer Res (2008) 1.34
Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma. Carcinogenesis (2003) 1.33
Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat. Hypertension (2003) 1.32
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 1.30
Phase II trial of radio frequency ablation of renal cancer: evaluation of the kill zone. J Urol (2002) 1.30
Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res (2007) 1.28
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
Spontaneous regression of advanced cancer: identification of a unique genetically determined, age-dependent trait in mice. Proc Natl Acad Sci U S A (2003) 1.25
Ironing out cancer. Cancer Res (2011) 1.25
Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol (2008) 1.24
Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem (2002) 1.23
Multimodality imaging of lymphocytic migration using lentiviral-based transduction of a tri-fusion reporter gene. Mol Imaging Biol (2004) 1.23
Branched-chain amino acid catabolism: unique segregation of pathway enzymes in organ systems and peripheral nerves. Am J Physiol Endocrinol Metab (2003) 1.21
MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol (2008) 1.20
Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene (2003) 1.20
Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol (2008) 1.20
Angiotensin-(1-7) and baroreflex function in nucleus tractus solitarii of (mRen2)27 transgenic rats. J Cardiovasc Pharmacol (2008) 1.20
Radiology report clarity: a cohort study of structured reporting compared with conventional dictation. J Am Coll Radiol (2010) 1.17
A systems biology view of cancer. Biochim Biophys Acta (2009) 1.17
Iron chelation in the biological activity of curcumin. Free Radic Biol Med (2006) 1.17
Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell (2007) 1.17
Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor. Mol Cell Biol (2008) 1.15
The role of iron chelation in cancer therapy. Curr Med Chem (2003) 1.15
Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol (2004) 1.15
Excess capacity of the iron regulatory protein system. J Biol Chem (2007) 1.14
Aortic stiffness increases upon receipt of anthracycline chemotherapy. J Clin Oncol (2009) 1.14
Angiotensin peptides as neurotransmitters/neuromodulators in the dorsomedial medulla. Clin Exp Pharmacol Physiol (2002) 1.14
Leptin impairs cardiovagal baroreflex function at the level of the solitary tract nucleus. Hypertension (2009) 1.14
Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Res (2003) 1.13
Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res (2003) 1.13
Conducting economic evaluations alongside multinational clinical trials: toward a research consensus. Am Heart J (2005) 1.12
Interstitial diphtheria toxin-epidermal growth factor fusion protein therapy produces regressions of subcutaneous human glioblastoma multiforme tumors in athymic nude mice. Clin Cancer Res (2005) 1.11
Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. Endocrinology (2010) 1.11
Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization. J Biol Chem (2010) 1.11
The transplant iron score as a predictor of stem cell transplant survival. J Hematol Oncol (2009) 1.10
Activation of local chorionic villi angiotensin II levels but not angiotensin (1-7) in preeclampsia. Hypertension (2008) 1.10
Bioinformatics tools for cancer metabolomics. Metabolomics (2011) 1.10
A diphtheria toxin-epidermal growth factor fusion protein is cytotoxic to human glioblastoma multiforme cells. Cancer Res (2003) 1.09
Thermal ablation therapeutics based on CN(x) multi-walled nanotubes. Int J Nanomedicine (2007) 1.09